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miR-126, miR-25, miR-205, miR-183, miR-125b) were measured by
qRT-PCR and normalized to miR-16.
Concentrations of four miRNAs (miR-19b, miR-21, miR-25,
miR-183) were significantly different in lung cancer versus
healthy individuals (p<0.05, T-test, two-sided). Two miRNAs were
upregulated (miR-19b, miR-21), two were downregulated (miR-25,
miR-183) in cancer patients. Four miRNAs (miR-19b, miR-126,
miR-25, miR-205) were found to be differentially regulated in
SCC patients when compared to healthy controls. In AC patients
only two miRNAs (miR-19b, miR-183) were differently expressed.
Thus, cancer subtypes have different input into overall picture.
Receiver Operating Characteristic (ROC) curve analysis of dif-
ferentially expressed miRNAs in total study population and
subtype-based groups showed that miR-19b has highest predic-
tive value for total population and SCC patients, while miR-183
was more effective in discriminating patients with AC. All miR-
NAs except miR-21 showed strong bias towards one of the
subtypes. Presumably a combination of miRNAs with opposite
bias should provide a more potent diagnostic tool for cancer
detection in total population than individual miRNAs or panels
of miRNAs that are specific to one cancer subtype. Indeed,
stepwise binary logistic regression has identified the combination
of miR-19b and miR-183 to be a strong prediction of disease in
total population and yielded a solid increase in AUC: 0,990
(miR-19b+miR-183) versus 0,806 (miR-19b) or 0,924 (miR-183). This
combination can be used to identify lung cancer with 94.7%
sensitivity and 95.2% specificity.
Thus, biological aspects such as tumor genetics and pheno-
type, stage of disease, response to therapy, and other meaningful
tumor properties of such heterogeneous malignancies as LC can
interfere with contents and composition of cell-free miRNA pool.
Wide profiling of circulating miRNAswill specify biomarkers of LC
phenotypes and improve non/less-invasive LC diagnostics.
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The development of individual medicine is a very important
part of the whole health care system and especially of the oncol-
ogy patients’ treatment. The predictive markers could help to
prevent the development of the different diseases. Individual risk
assessment is based on the study of polymorphisms in genes
specific to different pathologies, especially those with a signifi-
cant social impact, such as lung cancer.
Like many other cancers, lung cancer is a multi-factorial
disease. The tumor suppressor genes are important in its patho-
genesis. One such very important gene is TP53, which encodes
the p53 tumor suppressor protein. It regulates the activation of
specific cellular processes and signaling pathways involved in
regulation, recognition of signals inside the cell, coordination of
metabolic processes, genome repair, cell division and death
(apoptosis), and interactions between cells. Insufficient produc-
tion or property modification of this protein leads to the develop-
ment of serious diseases, including lung cancer.
The TP53 gene has a number of polymorphic markers; the
Arg72Pro and the Gln157Lys markers are very important in case
of lung cancer. They are located in the DNA-binding domain of
TP53 at exons that play essential structural and chemical roles
in the contact between the p53 protein and specific DNA
sequences that constitute the p53 response elements. These
mutations result in a significant loss of DNA-binding activity
and transactivation capacity (P. Hainaut and M. Hollstein, 2000).
We studied the association of polymorphic markers Arg72Pro
and Gln157Lys of TP53 gene with the risk of nonsmall cell lung
cancer (NSCLC) in patients from the Moscow region. Our study
included 88 patients with NSCLC, 160 healthy persons as a control
for Arg72Pro and 60 healthy persons as a control for Gln157Lys.
We used PCR-RLFP analysis to identify the alleles of the polymor-
phic markers.
We observed higher frequencies of the markers predisposition
genotypes in group of patients then in control group. The distri-
bution frequency of Pro/Pro genotype Arg72Pro marker was
0.307 in the group of patients and 0.075 in the control. For the
Gln157Lys marker the Lys/Lys genotype was not observed. The
frequency of Gln/Lys genotype Gln157Lys marker was 0.377 in
patients and 0.106 in the control. We found the association of
both markers with the risk of NSCLC development. The genotype
Pro/Pro of Arg72Pro marker showed the increasing of NSCLC risk:
OR = 5.46, p = 8  106. The presence of Gln/Lys genotype of
Gln157Lys marker also led to increased risk of cancer develop-
ment: OR = 5.10, p = 0.002.
Our results suggest the importance of studied polymorphic
markers for risk of NSCLC assessment. The status of the Arg72Pro
and the Gln157Lys markers of TP53 gene can serve as an indepen-
dent prognostic indicator in this type of cancer.
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Background: There is increasing evidence that BRCA1-related
DNA-repair defects determine sensitivity to certain agents, such
as platinum-based chemotherapy. There is a lot of evidence about
a link between TNBC and BRCA1 deficiency. Many clinical
characteristics and molecular features are shared by sporadic
triple-negative breast cancer and BRCA1-associated breast
cancer. The majority of BRCA1-related breast cancers are of
basal-like/triple-negative phenotype. Identification of specific
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